RxDoctor Payments Data

Guy Livnat, MD

Pulmonary Disease · Greenbrae, CANPI 1881682656

Payments from drug & device makers

$1,595in general payments, 2019–2025

Across 65 payments — averaging $24.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$368
  • GSK$332
  • AstraZeneca$204
  • Insmed, Inc.$200
  • Inari Medical, Inc.$195
  • Actelion Pharmaceuticals US, Inc.$101
  • plus $195 from 8 others

What the payments were for

  • Food & beverage$1,55297%
  • Education$423%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,595 in reported general payments places this provider in the 50th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Medicare billing

Part B allowed, 2024
$71,460
Medicare patients
281
Services billed
504

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate27$346,886
Trelegy ElliptaFluticasone/Umeclidin/Vilanter114$120,648
NucalaMepolizumab12$108,345
Spiriva RespimatTiotropium Bromide121$87,276
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr104$59,184
Breztri AerosphereBudesonide/Glycopyr/Formoterol35$37,083
Incruse ElliptaUmeclidinium Bromide62$31,825
Breo ElliptaFluticasone/Vilanterol46$20,442
Stiolto RespimatTiotropium Br/Olodaterol Hcl23$16,648
Arnuity ElliptaFluticasone Furoate46$13,913
Atrovent HfaIpratropium Bromide11$11,814
SymbicortBudesonide/Formoterol Fumarate33$9,193
Combivent RespimatIpratropium/Albuterol Sulfate14$6,727
BreynaBudesonide/Formoterol Fumarate44$6,517
Advair HfaFluticasone Propion/Salmeterol18$4,858

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat$368$457,538185 claims
GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta, Breo Ellipta$332$354,357384 claims
AstraZenecaBreztri Aerosphere, Symbicort$204$46,27668 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,261 pulmonary disease providers in California.

Other pulmonary disease in Greenbrae

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →